Which Regulatory Framework Applies to PMCF?
PMCF is part of the requirements of MDR 2017/745 on clinical evaluation and post-market surveillance. It is described in particular in Annex XIV, Part B, which presents PMCF as a continuous process for updating the clinical evaluation.
Two MDCG guidance documents are particularly used by manufacturers and notified bodies:
- MDCG 2020-7, for the PMCF plan
- MDCG 2020-8, for the PMCF evaluation report
These documents do not replace the MDR, but they provide an expected structure for documenting the PMCF strategy, collection methods, results obtained, and their impact on the clinical evaluation.
PMCF must also remain connected to PMS documentation. Depending on the device class, post-market data feed into the PMS Report or the PSUR, as well as updates to the CER, the Clinical Evaluation Report.
What Is PMCF Used For in Practice?
PMCF is first used to confirm that safety, performance, and clinical benefit remain valid over time. The data collected after commercialization may relate to broader populations, more varied practices, or contexts of use that differ from those documented before CE marking.
It also helps detect clinical signals that were not visible or sufficiently documented at the start: emerging risks, rare effects, late effects, misuse, or off-label uses.
Finally, it feeds regulatory documentation: CER, PMS documentation, and, where applicable, PSUR. PMCF therefore works as a continuous loop: plan, collect, analyze, document, update, and then reassess.
Which Deliverables Are Expected?
PMCF is materialized through several key documents. They must be consistent with each other and integrated into the device technical documentation.
```html
PMCF Deliverables
| Deliverable |
Role |
| PMCF Plan |
Defines the objectives, methods, populations, timeline, and data to be collected. |
| PMCF Evaluation Report |
Analyzes the results obtained and their clinical implications. |
| CER |
Integrates PMCF conclusions into the updated clinical evaluation. |
| PMS Report or PSUR |
Includes post-market data according to the device risk class. |
| Risk Management Documentation |
May be updated if PMCF data identify new risks or modify the existing evaluation. |
```
In practice, the PMS Report applies to Class I devices, while the PSUR applies to Class IIa, IIb, and III devices.
The challenge is not only to produce these documents. It is to show that the data collected are relevant, analyzed, and used to update the device evaluation.
Which Methods Can Be Used to Collect PMCF Data?
Collection methods depend on the device, its risk class, its clinical history, and the questions that remain open.
The most structured approaches include dedicated PMCF studies, post-market observational studies, registries, cohort follow-up, or multicenter studies. These formats are often necessary when the available data are not sufficient to meet clinical or regulatory expectations.
Other methods can complement data collection: patient questionnaires, healthcare professional questionnaires, quality-of-life measures, real-world use data, performance data in routine clinical practice, or longitudinal follow-up.
ePRO tools can be useful when PMCF relies on patient-reported data: symptoms, quality of life, satisfaction, tolerance, ease of use, or long-term perception. The value lies in structuring collection, limiting manual entry, and facilitating follow-up over time.
Depending on the PMCF protocol, an eCRF can also be used to collect data entered by investigators or healthcare professionals. In some cases, hybrid or remote approaches can also help follow participants without multiplying travel constraints.
Can PMCF Be Adapted?
PMCF is expected under the logic of the MDR, but its level of intensity must be proportionate. Not all devices require the same volume of data or the same collection methods.
The intensity of PMCF depends in particular on:
- the device risk class
- its clinical history
- the data already available
- the level of innovation
- residual risks
- remaining clinical uncertainties
- notified body expectations
When the manufacturer considers that PMCF is not necessary, this position must be justified and documented in the clinical evaluation. In practice, this justification is harder to defend for high-risk devices, implantable devices, or devices for which clinical data remain limited.
What Are the Risks of Insufficient PMCF?
Poorly designed or poorly executed PMCF can weaken the entire clinical dossier.
The consequences can be concrete: insufficient clinical data, difficulty confirming the benefit-risk ratio, notified body findings, requests for additional data, delays in certification processes, or difficulties maintaining an up-to-date clinical evaluation.
The risk is not only documentary. If post-market data are not collected or analyzed correctly, the manufacturer may miss useful signals on safety, performance, real-world use, or the limits of the device.
Why Digitize PMCF Data Collection?
PMCF can quickly become complex when data remain scattered across Excel files, emails, paper questionnaires, separate databases, and manual exports. This fragmentation complicates analysis, reduces traceability, and increases the workload needed to prepare regulatory deliverables.
A digital approach can help structure collection from the start: standardized forms, longitudinal follow-up, eCRF and ePRO data, reminders, dashboards, usable exports, and traceability of actions.
The objective is not to digitize for the sake of digitizing. The challenge is to secure the data chain, from collection through to analysis, in order to facilitate updates to the CER, PMCF report, PMS Report, or PSUR.
PMCF is an essential component of post-market clinical follow-up for medical devices under the MDR. It helps maintain the clinical evaluation up to date, document the benefit-risk ratio, and respond more robustly to notified body expectations.
Its value depends above all on the quality of the strategy implemented: relevant clinical questions, appropriate methods, structured collection, regular analysis, and integration of results into regulatory documentation.
When well designed, PMCF helps the manufacturer monitor the device over time, with clinical data that are genuinely usable.
